ITM AG (Isotopen Technologien Munchen, Germany), a privately held radiopharmaceutical biotech company, announced today that is has signed two strategic agreements with Telix Pharmaceuticals Limited for the global supply of ITM’s highly pure therapeutic radioisotope no-carrier-added Lutetium-177 (n.c.a. 177Lu). ITM’s n.c.a. 177Lu, known under the brand name EndolucinBeta®, is a high-purity version of the beta-emitting radioisotope Lutetium-177 that can be linked to a variety of tumor-specific targeting molecules for Targeted Radionuclide Therapy and has demonstrated significant anti-tumor effects in clinical and commercial use.
To read more please visit: